#47 - 600% in 3 Days: the execution playbook behind Abivax’s breakthrough in IBD | Pharma Minds

In this podcast episode, Marc de Garidel, CEO of Abivax, recounts the journey of turning around a biotech company facing difficulties. He details his initial immersion in gastroenterology, the establishment of a long-term vision focusing on ulcerative colitis and Crohn's disease, and the strategic decision to pursue NASDAQ listing for funding. Marc highlights the challenges of executing Phase 3 trials, building a US-based team, and differentiating their drug, Obifazimod, through its unique mechanism of action. He shares the pivotal moment of receiving positive trial results, the subsequent surge in stock value, and the ambitious plans for US launch and potential partnerships for global expansion, emphasizing the importance of focus, risk mitigation, and a transparent company culture.

Outlines

Sign in to continue reading, translating and more.

Continue

#47 - 600% in 3 Days: the execution playbook behind Abivax’s breakthrough in IBD

Pharma Minds

Introduction to Abivax's Journey and Initial Strategy

Defining a Long-Term Vision and Pursuing NASDAQ Access

Building US Infrastructure and Addressing Phase 3 Challenges

Differentiating the Drug and Mitigating Risks

Transforming Phase 2 Data into a Successful Phase 3 Strategy

The Ambition Behind an Ambitious Phase 3 and Building a Culture of Transparency

Leadership, Long-Term Vision, and the Readout Day

From Near Bankruptcy to NASDAQ Star and a $750 Million Raise

Launch Strategy, Market Perception, and Big Pharma's View

The Initial Intrigue and the Importance of Execution

#47 - 600% in 3 Days: the execution playbook behind Abivax’s breakthrough in IBD

Pharma Minds

00:00Introduction to Abivax's Journey and Initial Strategy

Introduction to Abivax's Journey and Initial Strategy

05:21Defining a Long-Term Vision and Pursuing NASDAQ Access

Defining a Long-Term Vision and Pursuing NASDAQ Access

10:11Building US Infrastructure and Addressing Phase 3 Challenges

Building US Infrastructure and Addressing Phase 3 Challenges

16:33Differentiating the Drug and Mitigating Risks

Differentiating the Drug and Mitigating Risks

21:21Transforming Phase 2 Data into a Successful Phase 3 Strategy

Transforming Phase 2 Data into a Successful Phase 3 Strategy

26:36The Ambition Behind an Ambitious Phase 3 and Building a Culture of Transparency

The Ambition Behind an Ambitious Phase 3 and Building a Culture of Transparency

32:36Leadership, Long-Term Vision, and the Readout Day

Leadership, Long-Term Vision, and the Readout Day

39:55From Near Bankruptcy to NASDAQ Star and a $750 Million Raise

From Near Bankruptcy to NASDAQ Star and a $750 Million Raise

45:53Launch Strategy, Market Perception, and Big Pharma's View

Launch Strategy, Market Perception, and Big Pharma's View

53:27The Initial Intrigue and the Importance of Execution

The Initial Intrigue and the Importance of Execution